Dr. Charles Ryan Discusses IMAAGEN Trial Update for Prostate Cancer

Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, provides an update to the IMAAGEN trial, which explored the effects of abiraterone acetate (Zytiga) and low-dose prednisone on prostate-specific antigen (PSA) and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer (CRPC).

The phase II study is examining an important patient population, as there is no standard of care for them, Ryan explains, and most patients progress to metastatic disease.

The findings show that the addition of 5 mg of prednisone was not associated with significant adverse events, he says. Additionally, there was a high PSA response proportion of 90%, the time to PSA progression was 28 months, and the time to metastatic progression has not been determined.